Nature Communications (Nov 2018)
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma
- Elizabeth C. Randall,
- Kristina B. Emdal,
- Janice K. Laramy,
- Minjee Kim,
- Alison Roos,
- David Calligaris,
- Michael S. Regan,
- Shiv K. Gupta,
- Ann C. Mladek,
- Brett L. Carlson,
- Aaron J. Johnson,
- Fa-Ke Lu,
- X. Sunney Xie,
- Brian A. Joughin,
- Raven J. Reddy,
- Sen Peng,
- Walid M. Abdelmoula,
- Pamela R. Jackson,
- Aarti Kolluri,
- Katherine A. Kellersberger,
- Jeffrey N. Agar,
- Douglas A. Lauffenburger,
- Kristin R. Swanson,
- Nhan L. Tran,
- William F. Elmquist,
- Forest M. White,
- Jann N. Sarkaria,
- Nathalie Y. R. Agar
Affiliations
- Elizabeth C. Randall
- Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School
- Kristina B. Emdal
- Department of Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Janice K. Laramy
- Department of Pharmaceutics, College of Pharmacy, University of Minnesota
- Minjee Kim
- Department of Pharmaceutics, College of Pharmacy, University of Minnesota
- Alison Roos
- Department of Cancer Biology, Mayo Clinic
- David Calligaris
- Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School
- Michael S. Regan
- Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School
- Shiv K. Gupta
- Department of Radiation Oncology, Mayo Clinic
- Ann C. Mladek
- Department of Radiation Oncology, Mayo Clinic
- Brett L. Carlson
- Department of Radiation Oncology, Mayo Clinic
- Aaron J. Johnson
- Department of Immunology, Mayo Clinic
- Fa-Ke Lu
- Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School
- X. Sunney Xie
- Department of Chemistry and Chemical Biology, Harvard University
- Brian A. Joughin
- Department of Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Raven J. Reddy
- Department of Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Sen Peng
- Cancer and Cell Biology Division, Translational Genomics Research Institute
- Walid M. Abdelmoula
- Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School
- Pamela R. Jackson
- Mathematical NeuroOncology Lab, Department of Neurosurgery, Mayo Clinic
- Aarti Kolluri
- Mathematical NeuroOncology Lab, Department of Neurosurgery, Mayo Clinic
- Katherine A. Kellersberger
- Bruker Daltonics
- Jeffrey N. Agar
- Department of Chemistry and Chemical Biology, Northeastern University
- Douglas A. Lauffenburger
- Department of Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Kristin R. Swanson
- Mathematical NeuroOncology Lab, Department of Neurosurgery, Mayo Clinic
- Nhan L. Tran
- Department of Cancer Biology, Mayo Clinic
- William F. Elmquist
- Department of Pharmaceutics, College of Pharmacy, University of Minnesota
- Forest M. White
- Department of Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Jann N. Sarkaria
- Department of Radiation Oncology, Mayo Clinic
- Nathalie Y. R. Agar
- Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School
- DOI
- https://doi.org/10.1038/s41467-018-07334-3
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 13
Abstract
Despite major drug discovery efforts, the therapeutic options for glioblastoma (GBM) remain inadequate. Here they analyze patient-derived xenograft model of GBM to quantitatively map distribution and cellular response to the EGFR inhibitor erlotinib, and report heterogeneous erlotinib delivery to intracranial tumors to be inadequate to inhibit EGFR signaling.
